1. Introduction {#j_med-2017-0012_s_001}
===============

Liver injury is one of the most common complications in patients after kidney transplantation. The incidence of liver injuries soon after kidney transplantation is 20%\~50%, and is the second most common postoperative complication post transplantation \[[@j_med-2017-0012_ref_001]\]. It has a serious impact on patients' life expectancy and life quality. It is recommended to comprehensively assess the status of the liver before transplantation \[[@j_med-2017-0012_ref_002]\]. Liver function examinations and relevant morphological examinations should be performed regularly after the transplantation. Once liver function abnormalities occur, drug-drug interaction must be avoided when liver-protective medicines are applied in order to maintain the concentrations of tacrolimus (Tac) and cyclosporine (CsA). Liver function abnormalities occurring after kidney transplantation are difficult to treat \[[@j_med-2017-0012_ref_003]\], so their prevention is very important. Another study \[[@j_med-2017-0012_ref_004]\] has shown that monitoring liver functions regularly after kidney transplantation, discovering possible liver injuries induced by medicines early, adjusting the immunosuppressant treatment scheme and strengthening liver-protective treatment are beneficial for achieving satisfactory outcomes. Bicyclol(4,40-dimethoxy-5,6,50,60-dimethylene-dioxy-2,20-dicarboxylate biphenyl) is a liver protectant for patients with various liver diseases used in many countries. Bicyclol tablets possess obvious anti-inflammatory and liver-protective functions \[[@j_med-2017-0012_ref_005]\], can prevent and control liver injuries at an early stage after kidney transplantation, and improve prognosis of kidney transplantation without affecting the pharmacokinetics of Tac \[[@j_med-2017-0012_ref_006]\]. In order to assess the preventive and protective function of Bicyclol tablets on drug induced liver injuries (DILIs) after kidney transplantation, this retrospective analysis was performed with 1600 patients who accepted kidney transplantations at our hospital from January 2009 to May 2015.

2. Materials and methods {#j_med-2017-0012_s_002}
========================

2.1. Kidney transplant cases {#j_med-2017-0012_s_002_s_001}
----------------------------

Source(s) of the transplanted kidneys: In this study, the source(s) of kidneys used in transplant came from 2 groups. 1. Immediate family member donors: 480 cases. These were living donor from relatives who are immediate family members of the acceptors of kidney transplant.2. Heart and brain death donors: 265 cases. The source of heart and brain death donors was the Red Cross Organ Donation Management Center in China.

The medical records of 1600 patients who accepted allogenic kidney transplantations at our hospital from Januaury 2009 to May 2015 were collected and investigated. The age of patients ranged from 5 to 60 years, including both males and females. A total of 615 cases with serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) abnormalities, HBV DNA quantity \> 102 IU/ml, taking other liver-protective medicines and patients with Hepatitis C infection were initially excluded. The remaining 985 cases were divided into the prevention group and the control group according to whether Bicyclol tablets were regularly administered or not after the operation. Cases with missing data, rejection reaction, non-alcoholic and alcoholic liver diseases, autoimmune hepatitis and serious infections were also excluded. Finally, data statistics and analysis of occurrence of liver injuries in the early postoperative period in all included patients were performed (As shown in [Figure 1](#j_med-2017-0012_fig_001){ref-type="fig"}). Data was collected and quality control was performed according to the scheme in the survey forms.

![Case selection flow chart](med-12-062-g001){#j_med-2017-0012_fig_001}

2.2. Ethics statement {#j_med-2017-0012_s_002_s_002}
---------------------

This study was approved by the ethics committees of our hospital. No conflict of interest exists in this study, and none of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given.

In this study, kidney donors' informed consent process is as follows: (1) Immediate family member donors: a. Fill in living organ donation letter of intent, agreed and signed by immediate family members, and acknowledged and agreed by acceptor family members; b.Pass donor comprehensive inspection, in line with kidney donation conditions, no contraindication for kidney surgery; c. the local police station issues acceptor immediate family member certificates, reviewed and discussed by "Human Organ Transplant Clinical Application and Ethics committee" of our hospital, and approved by the Provincial Health Department to implement a kidney transplant for the acceptors. (2) Heart and brain death donors: Donors assigned by China's human organ distribution and computer system and approved by the Human Organ Transplant Clinical Application and Ethics Commission of our hospital to implement a kidney transplant for the acceptors.

2.3. Study method {#j_med-2017-0012_s_002_s_003}
-----------------

### 2.3.1. Grouping method {#j_med-2017-0012_s_002_s_003_s_001}

This was a retrospective cohort study. Patients who met the criteria were divided into two groups: (1) the prevention group: patients taking Bicyclol tablets after kidney transplantation (manufactured by Beijing Union Pharmaceutical Factory, 25 mg/tablet, 25 mg three times daily,12 weeks); Criteria for determining whether patients would receive Bicyclol tablets include: medication dispensed by nurses with dosage as prescribed under direct observationfor inpatients; Telephone follow-up of patients' medications and checking the amount of medicine distributed in pharmacy to outpatients. The control groupconsisted of patients not taking any liver-protective medicine after kidney transplantation.

### 2.3.2. Data collected {#j_med-2017-0012_s_002_s_003_s_002}

Demographics of patient cases were collected, including gender, age, height, weight, smoking, drinking, etc.. (2) Medical histories of patients was recorded, including primary diseases requiring kidney transplantation, past diseases and treatment history, coexistent diseases or symptoms, drug combinations before kidney transplantation, drug allergy history, etc.. Patient lab results were collected including symptoms and signs examinations and liver function indexes (ALT and AST) before kidney transplantation and at 4, 8 and 12 weeks after kidney transplantation, preoperative HBV DNA quantitative determination and HBsAg qualitative determination. The immunosuppressant scheme and terminal point of the investigation (DILI occurred within three months after the operation) were also recorded.

2.4. Investigation methods and quality control {#j_med-2017-0012_s_002_s_004}
----------------------------------------------

In-hospital record data was interrogated, survey forms were created and a database was set up to track data. Double-person recording for contrasting error-checking was adopted. Up to 10% samples were selected randomly. When the qualified rate was above 90% and the core indexes were above 95%, the data was regarded as qualified. In order to guarantee authenticity of the data and for reducing errors, quality control was performed throughout the investigation process including personnel training, pre-survey (By questionaire and on-the-spot statistics, the survey forms is examined, which is designed in advance), on-site investigation, data processing and analysis.

2.5. Main observation indexes {#j_med-2017-0012_s_002_s_005}
-----------------------------

Main observation indexes included ALT and AST. When ALT and/or AST levels were more than 2 times the upper limit of normal values (ULN), it was suggestive of liver injuries. The occurrence of liver injuries in both groups were counted and their causative factors analyzed.

2.6. Statistical analysis {#j_med-2017-0012_s_002_s_006}
-------------------------

Data was summarized using EPIDATA 3.1 software, sample capacity was calculated using PASS 11.0 software, and statistical analysis was performed using SPSS 17.0 statistical software. The incidence of liver injuries after kidney transplantation is about 30% \[[@j_med-2017-0012_ref_007]--[@j_med-2017-0012_ref_008]\]. The incidence of liver injuries is about 18% in patients who took Bicyclol tablets as preventive liver-protective treatment \[[@j_med-2017-0012_ref_009]\]. Using PASS 11.0 software (a= 0.05, p= 0.10, *two-sided test*), every group needed at least 265 patients. Inter-group differences in continuous variables were analyzed using independent-samples t-test. Inter-group differences in categorical data were analyzed using χ^2^-test. Inter-group differences in ordinal categorical data were assessed using Wilcoxon test; non-normal distribution data were analyzed using non-parametric test. The causative factors of liver injuries were determined using monofactorial and multifactorial logistic regression analyses. All statistical tests were twosided, and P\< 0.05 was considered to be statistically significant.

3. Results {#j_med-2017-0012_s_003}
==========

3.1. Selected cases {#j_med-2017-0012_s_003_s_001}
-------------------

A total of 745 cases were included in this analysis, of which 456 were in the prevention group and 289 in the control group. Both groups had no significant differences in age, gender, BMI, HBsAg, maintenance immunosuppression, ALT and AST at baseline (P\> 0.05). ([Table 1](#j_med-2017-0012_tab_001){ref-type="table"}).

###### 

Comparison of baseline characteristics of the two groups

  General condition                   Prevention group (n= 456)   Control group (n= 289)   statistical quantity   P
  ----------------------------------- --------------------------- ------------------------ ---------------------- -------
  **Age**                                                                                  *χ*^2^= 1.306          0.253
   ≥ 40                               91                          48                                              
   \< 40                              365                         241                                             
  **Gender**                                                                               *χ*^2^= 0.794          0.373
   male                               298                         198                                             
   female                             158                         91                                              
  **BMI**                                                                                  *χ*^2^= 2.062          0.151
   ≥25                                102                         78                                              
   \< 25                              354                         211                                             
  **HBsAg**                                                                                *χ*^2^= 0.587          0.444
   positive                           31                          24                                              
   negative                           425                         265                                             
  **Primary diseases**                                                                     *χ*^2^= 10.511         0.015
   chronic renal failure              304                         175                                             
   hypertensive nephropathy           85                          45                                              
   diabetic nephropathy               56                          55                                              
   other                              11                          14                                              
  **maintenance immunosuppression**                                                        *χ*^2^= 0.118          0.732
   MMF+ CsA + Pred                    204                         133                                             
   MMF+ Tac + Pred                    252                         156                                             
  **baseline transaminases**                                                                                      
   ALT(U/L)                           19.13 ± 13.14               17.70 ± 11.27            *t*= 1.529             0.127
   AST(U/L)                           21.71 ± 8.84                22.04 ± 7.96             *t*= 0.525             0.600

MMF: mycophenolate mofetil, Tac: tacrolimus, CsA: cyclosporine, Pred: prednisone. The initial dosages of CsA and Tac were 6-8 mg·kg-1·d-1 and 0.08-0.15 mg·kg-1·d-1, respectively, the dosage should be adjusted according to blood concentration and clinical symptoms during the treatment. Trough levels were maintained at 180-220ng/ml and 5-10ng/ml, respectively)

3.2. Analysis of the occurrence of liver injuries and their influencing factors {#j_med-2017-0012_s_003_s_002}
-------------------------------------------------------------------------------

Monofactorial analysis of the occurrence of liver injuries revealed 82 cases in both groups at early stage liver injury after the operation. Group (prevention and control group), HBsAg status, age and maintenance of immunosuppression significantly affected the occurrence of liver injuries at an early stage after the operation (P\< 0.05). Of the 82 cases, 22 were in the prevention group (4.82%) and 60 in the control group (20.76%), and the difference of liver injury incidence between the groups was statistically significant (P= 0.001) ([Table 2](#j_med-2017-0012_tab_002){ref-type="table"}). After controlling for age, HBsAg status and maintenance of immunosuppression, the OR (95% CI) of the prevention group was 0.197 (0.116, 0.334) as compared to the control group, and the difference was statistically significant (P= 0.001) ([Table 3](#j_med-2017-0012_tab_003){ref-type="table"}).

###### 

Monofactorial analysis of the occurrence of liver injuries

  Factor                              Number of patients with liver injuries   Number of patients without liver injuries   P        Unadjusted OR (95% CI)
  ----------------------------------- ---------------------------------------- ------------------------------------------- -------- ------------------------
  **Groups**                                                                                                               0.0001   0.193(0.116,0.323)
   Prevention group                   22                                       434                                                  
   Control group                      60                                       229                                                  
  **Age**                                                                                                                  0.046    1.711(1.009,2.900)
   ≥ 40                               22                                       117                                                  
   \< 40                              60                                       546                                                  
  **Gender**                                                                                                               0.095    1.558(0.925,2.625)
   male                               61                                       425                                                  
   female                             21                                       228                                                  
  **BMI**                                                                                                                  0.824    0.940(0.546,1.618)
   ≥ 25                               19                                       161                                                  
   \< 25                              63                                       502                                                  
  **HBsAg**                                                                                                                0.000    5.253(2.845,9.698)
   positive                           19                                       36                                                   
   negative                           63                                       627                                                  
  **Primary diseases**                                                                                                     0.443    
   Chronic renal failure              47                                       432                                                  
   Hypertensive nephropathy           18                                       112                                         0.189    1.477(0.826,2.643)
   Diabetic nephropathy               15                                       96                                          0.254    1.436(0.771,2.675)
   Other                              2                                        23                                          0.766    0.799(0.183,3.497)
  **maintenance immunosuppression**                                                                                        0.021    1.727(1.086,2.746)
   MMF+ CsA + Pred                    47                                       287                                                  
   MMF+ Tac + Pred                    35                                       368                                                  

###### 

Multifactorial analysis of the occurrence of liver injuries

  Factor                                                                  Wald Chi-square   P       Adjusted OR (95% CI)
  ----------------------------------------------------------------------- ----------------- ------- ----------------------
  **Groups** (prevention or control)                                      36.459            0.001   0.197(0.116,0.334)
  **Age** (≥ 40 or \< 40 years)                                           0.126             0.722   1.116(0.610,2.042)
  **HBsAg** (positive or negative)                                        19.947            0.001   4.817(2.416,9.603)
  **Maintenance immunosuppression** (MMF+ CsA+ Pred or MMF+ Tac + Pred)   4.097             0.043   1.659(1.016,2.710)

4. Discussion {#j_med-2017-0012_s_004}
=============

The factors causing liver injuries after kidney transplantation are very complicated, including medications, chronic hepatitis B infectio (CHB), and biliary duct infection. Many of the liver injuries occurring at an early stage after kidney transplantation are drug-induced \[[@j_med-2017-0012_ref_010]\]. The pathogenic mechanism of liver injuries caused by CHB involves suppression of the patient's immunity by immunosuppressants and active HBV replication \[[@j_med-2017-0012_ref_011]\]. Prognosis of kidney transplantation can be improved if the clinical treatment can effectively prevent or control liver injuries occurring at an early stage after the transplantation.

In this study, it is proposed that the liver injuries occurring at an early stage after kidney transplantation are mainly DILIs. First, it is thought that liver injuries are mainly caused by commonly used immunosuppressants such as CsA, Tac, Sirolimu (SRL), azathioprin (Aza), mycophenolate mofeti (MMF) and glucocorticoid. Moreover, hepatotoxicity of immunosuppressants negatively impacts the clinical effect after organ transplantations, and can even lead to hepatic failure or death \[[@j_med-2017-0012_ref_012]\]. DILIs often occur between two weeks and three months after kidney transplantation, and the main symptoms are transaminase and bilirubin elevation \[[@j_med-2017-0012_ref_013]\]. Liver injuries induced by immunosuppressants may be related to the administration of large-dosage medicine, especially CNI, which can influence the stability and permeability of liver cell membranes by disturbing the membrane proteins' function of microbody. Simultaneously, it disturbs mRNA production and impacts the synthesis of DNA and ribosomes, thereby causing synthesis and secretion dysfunctions of protein and bile, finally impacting detoxification and other metabolic functions of the liver. Cases with liver injuries caused by autoimmune liver diseases, non-alcoholic or alcoholic liver diseases after the operation were excluded from this study. Cases with preoperative abnormal liver functions and HBV DNA \> 102 IU/ml were also excluded from this study. Patients with chronic HBV infection are more likely to develop DILI. This may be due to the fact that HBV-infected persons have poor drug tolerance and suffer from defects in drug metabolism; as a consequence hepatitis B virus may be reactivated with elevated ALT/AST, especially at reduced dose or withdrawal of immunosuppressive therapy.

The factors influencing liver injuries after kidney transplantation included groups (prevention and control group) (P= 0.001), HBsAg status (P= 0.000) and different maintenance immunosuppression regimes (P= 0.043). The risk of occurrence of liver injuries in the prevention group was 0.197 (95% CI:0.116, 0.334) times that of the control group, while that of patients with positive HBsAg was 4.817 (95% CI:2.416, 9.603) times that of patients with negative HBsAg. The risk of occurrence of liver injuries after application of MMF + CsA + prednisone (Pred) maintenance immunosuppression was 1.659 (95% CI:1.016, 2.710) times that of application of MMF + Tac + Pred maintenance immunosuppression. When liver injuries occur after kidney transplantation, the dosage of immunosuppressants should be reduced and liver-protective medicines should be administered. Rejection reaction or the necessity of a long-term liver protection treatment often occur because of excessive dosage reduction of immunosuppressants. This study revealed that the preventive application of Bicyclol tablets combined with maintenance immunosuppression treatment after kidney transplantation were protective factors against liver injuries and ensure successful treatment for the primary disease.

Bicyclol tablets possess intensive anti-inflammatory and liver-protective functions against liver injuries induced by different factors. They can improve impaired liver cell functions and relieve pathological injuries of the liver, and are widely administered abroad as in widely geographically. Bicyclol tablets can inhibit the expression and activity of nuclear transcription factor-κB (NF-κB) induced by inflammation, reduce proinflammatory factors including tumor necrosis factor α (TNF-α), IL-18 and inducible nitric oxide synthase (iNOS), inhibit inflammatory injuries and oxidative damage induced by the synthesis of oxygen radicals (ROS) and nitric oxide (NO) \[[@j_med-2017-0012_ref_014]--[@j_med-2017-0012_ref_015]\], prevent apoptosis of liver cells, stabilize liver cell membranes, improve mitochondrial function and protect the structure and functions of liver cell DNA \[[@j_med-2017-0012_ref_016]--[@j_med-2017-0012_ref_024]\], and to relieve liver cell injuries. Hence, Bicyclol tablets possess functions of anti-oxidation and protection of liver cell membranes, chondriosome and nucleus. Bicyclol tablets can protect mice from liver energy metabolism dysfunction and chondriosome dysfunction induced by paracetamol \[[@j_med-2017-0012_ref_017]\]. Theses tablets could prevent hepatotoxicity by enhancing the metabolism of Aflatoxin B1 \[[@j_med-2017-0012_ref_018]\] and prevent ConA liver injuries by inhibiting Fas/FasL mRNA expression and TNF-α release \[[@j_med-2017-0012_ref_019]\]. Chu and collegues \[[@j_med-2017-0012_ref_020]\] proved that Bicyclol tablets for liver-protective treatment combined with other basic liver-protective treatments can prevent the occurrence of liver injuries induced by antituberculosis drugs in patients with basic liver diseases, and guarantee successful antituberculosis treatment. Li et al \[[@j_med-2017-0012_ref_021]\] showed that Bicyclol tablets for liver-protective treatment combined with chemotherapy can reduce the occurrence and severity of DILIs in elderly cancer patients above 60 years, and guarantee the safety and tolerance of chemotherapy. Li Bing et al \[[@j_med-2017-0012_ref_022]\] showed that therapeutic dosage (25 mg, 3 times/d) of Bicyclol tablets does not affect the Tac blood concentration of patients who have accepted kidney transplantation. The liver-protective and enzyme lowering effects of BiCyclol are clear; it is safe for those with abnormal liver functions and normal Tac blood concentration. Laskow et al \[[@j_med-2017-0012_ref_023]\] reported that CsA's impact on the liver is greater than that of Tac, due to the following possible reasons: (1) FK506 possesses more intensive immunosuppressive action, which is about 100 times more than CsA, so the oral dosage is much less than CsA; (2) threshold concentration of liver injuries induced by Tac is much higher than the therapeutic window concentration range. In our study, the dosage of CsA and Tac should be adjusted according to blood concentration and clinical symptoms during treatment. We monitored trough levels of CsA and Tac once every 3 to 4 days during the perioperation period and once a week during the first three months post kidney transplantation in order to maintain a certain level ( 180-220ng/ml and 5-10ng/ml, respectively)., The results revealed that the risk of occurrence of liver injuries by MMF + CsA + Pred maintenance immunosuppression is higher than that of MMF + Tac + Pred maintenance immunosuppression, perhaps because the impact of CsA on liver functions is greater than Tac. Also, the risk of occurrence of liver injuries in patients with positive HBsAg is higher than those with negative HBsAg, because DILI can easily occur when kidney transplantation patients with viral hepatitis take immunosuppressants, due to the lower enzymatic activity of cytochrome CYP 3A4 and expression of mRNA in liver cells, and lower ALT as compared to healthy subjects, suggesting that drug metabolic defects exist in patients with HBV \[[@j_med-2017-0012_ref_024]\]·

5. Conclusions {#j_med-2017-0012_s_005}
==============

The preventive administration of Bicyclol tablets for liver-protective treatment was a protective factor against liver injuries at an early stage after kidney transplantation. Since this was a retrospective study with limited observation indexes, a large sample randomized control clinical study of DILI induced by anti-rejection medicines, especially a control study of hepatic histology qualitative and quantitative analyses should be performed. Interdisciplinary academic and experience exchange should be strengthened in order to assess the clinical value of Bicyclol tablets in preventive and liver-protective treatment of patients who have accepted maintenance immunosuppression.
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